Nuclea partners with AccuGenomics, Nuvera, 4/14
April 2014—Nuclea signed development deals with AccuGenomics and Nuvera Biosciences that will include validating two new assays in the treatment of chronic myeloid leukemia and breast cancer.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Automated pipetting systems, 4/14
April 2014—Eppendorf North America added five models to its epMotion range of automated pipetting systems. The epMotion 5075 system uses Eppendorf’s epBlue software and an intuitive software assistant concept that can be easily programmed and requires only initial training for new users.
Colorectal cancer screening kits, 4/14
April 2014—EntroGen expanded its line of colorectal cancer screening products to include the EntroGen K-Ras and N-Ras Mutation Analysis kits. The kits are updated to include coverage for exon 2, 3, and 4 mutations in both genes. The company obtained a CE IVD mark for these products.
Middleware user satisfaction, 4/14
April 2014—Siemens Healthcare Diagnostics’ CentraLink Data Management System achieved the highest rating for overall user satisfaction, according to the Middleware Market Monitor, a report published by Information Dynamics. The report reviews the current use of middleware solutions in the main hospital clinical laboratory and tracks changes in product usage or applications.
‘Universal’ NGS solutions, 4/14
April 2014—Qiagen announced the launch plans of products designed to reduce the challenges of bottlenecks in next-generation sequencing: sample preparation and bioinformatics. The products add to Qiagen’s portfolio of solutions designed to run with any NGS platform.
RBCX cleared on Spectra Optia system, 4/14
April 2014—Terumo BCT received FDA 510(k) clearance for red blood cell exchange on the Spectra Optia Apheresis System.
ELISA reagents, 4/14
April 2014—Vector Laboratories’ Avidin-HRP and Streptavidin-HRP are optimized to yield high signal-to-noise ratios in solid phase assays, such as ELISAs and blotting applications.
Audit Web site, 4/14
April 2014—Audit MicroControls launched a new Web site, adding online ordering, access to Auditor QC, peer review data retrieval, and search functions by instrument, analyte, or indication. It also offers information about quality control products, calibration verification/linearity products, Audit Ship, and Audit Faxback.
Control LQ Glycohemoglobin A1c, 4/14
April 2014—Audit MicroControls added to its line of products the Control LQ Glycohemoglobin A1c—a liquid bi-level reference control consisting of human blood–based solutions.
Dako, Merck team up, 4/14
April 2014—Dako entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.